

Embargo: July 16, 2009 at 5:40 PM (Brussels Time)

As customary, the Solvay group does not wish to react to the rumours reported by the press today.

The analysis of the various strategic options for Solvay's pharmaceutical activities is continuing, in all aspects indicated by the publication of April 22, 2009 (<http://www.solvaypress.com/pressreleases/0,,73457-2-0,00.htm>).

SOLVAY GROUP is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 29,000 people in 50 countries. In 2008, its consolidated sales amounted to EUR 9.5 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay is listed on the NYSE Euronext stock exchange in Brussels (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR). Details are available at www.solvay.com.

For further information please contact:

ERIK DE LEYE

Corporate Press Officer

SOLVAY S.A.

Tel: 32 2 509 7230

erik.deleye@solvay.com

www.solvaypress.com

PATRICK VERELST

Investor Relations

SOLVAY S.A.

Tel. 32 2 509 7243

patrick.verelst@solvay.com

www.solvay-investors.com

Ce communiqué de presse est également disponible en français – Dit persbericht is ook in het Nederlands beschikbaar